Prikaz osnovnih podataka o dokumentu
Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
dc.creator | Santibanez, Juan F. | |
dc.creator | Bjelica, Sunčica | |
dc.date.accessioned | 2021-04-20T12:59:41Z | |
dc.date.available | 2021-04-20T12:59:41Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 1574-8928 | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/892 | |
dc.description.abstract | Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases. | en |
dc.publisher | Bentham Science Publ Ltd, Sharjah | |
dc.relation | UBO | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175024/RS// | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175053/RS// | |
dc.rights | restrictedAccess | |
dc.source | Recent Patents on Anti-Cancer Drug Discovery | |
dc.subject | Cancer | en |
dc.subject | inflammation | en |
dc.subject | interleukin-17A (IL-17A) | en |
dc.subject | interleukin-17 Receptor A (IL-17RA) | en |
dc.subject | patents | en |
dc.subject | signaling | en |
dc.subject | therapies | en |
dc.title | Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation | en |
dc.type | article | |
dc.rights.license | ARR | |
dc.citation.epage | 144 | |
dc.citation.issue | 2 | |
dc.citation.other | 13(2): 133-144 | |
dc.citation.rank | M23 | |
dc.citation.spage | 133 | |
dc.citation.volume | 13 | |
dc.identifier.doi | 10.2174/1574892813666180220105958 | |
dc.identifier.pmid | 29468982 | |
dc.identifier.scopus | 2-s2.0-85048982610 | |
dc.identifier.wos | 000432224500001 | |
dc.type.version | publishedVersion |